...over the last five years and was CEO of Granngården AB from 2013 to 2015. CohBar Inc....
...strategy at Ovid Therapeutics Inc. (NASDAQ:OVID). Robin Sawka, BioCentury Staff Evox Therapeutics Ltd. BridgeBio Artax Biopharma Inc. Nucleix Ltd. IsoPlexis Corp. Centogene Immunicum AB CohBar Inc. CorMedix...

...Huffnagle was president of the joint replacement division at Stryker Corp. (NYSE:SYK). Mitochondria-based therapeutics company CohBar Inc....
...took the reins in December following the departure of CEO Simon Allen, will remain on CohBar’s...
...& acquisitions worldwide at Johnson & Johnson (NYSE:JNJ) in 2010. BioCentury Staff Algiax Pharmaceuticals GmbH Aquestive Therapeutics Inc. CDx Diagnostics CohBar Inc. Engitix...

...general manager for three manufacturing facilities at Hitachi Chemical Advanced Therapeutics Solutions LLC (Allendale, N.J.). Cohbar Inc....

...young mice. Next steps include designing a long-acting version of the peptide. (See "Raising the CohBar"...
...open reading frame of the 12S rRNA-c (MOTS-c) LICENSING STATUS: Patent application filed; licensed to CohBar Inc....

...DNA may deserve a second look as a source of therapeutic targets. A group from CohBar Inc....
...therapeutic targets might be encoded in mitochondrial DNA, although that has been the basis of CohBar's...
...has exclusively licensed all IP related to mitochondria-derived peptides to CohBar. Companies and Institutions Mentioned CohBar Inc....

...CohBar received $205,260 in funding from ADDF to develop CohBar's Humanin analog, a mitochondrial peptide to...
...will support a year-long research program, including in vivo testing of the compound for AD. CohBar's...
...peptide, which inhibits cell death pathways that are active in AD and other neurological disorders. CohBar Inc....